유전체학 시장 : 제품 유형, 기술, 샘플 유형, 자동화 레벨, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Genomics Market is projected to grow by USD 112.26 billion at a CAGR of 10.12% by 2032.

Genomics is moving from a research-intensive discipline into a core infrastructure layer for precision medicine, public health surveillance, agricultural biotechnology, population health, and biopharmaceutical discovery. The genomics industry is being shaped by sustained reductions in sequencing costs, broader access to next-generation sequencing, expanding clinical utility for rare disease and oncology testing, and rising demand for high-quality genomic data across healthcare systems.

Publicly available benchmarks from the National Human Genome Research Institute show that DNA sequencing costs have fallen dramatically since the Human Genome Project, enabling clinical and research use cases that were not commercially practical two decades ago. At the same time, national programs such as the United Kingdom's 100,000 Genomes Project, the U.S. All of Us Research Program, and population genomics initiatives in Asia-Pacific are accelerating the creation of reference datasets that support diagnostics, therapeutics, and preventive care.

For industry leaders, the genomics landscape is no longer defined only by sequencing throughput. Competitive advantage increasingly depends on integrated workflows that combine sample preparation, sequencing chemistry, bioinformatics, variant interpretation, secure cloud infrastructure, regulatory-grade data governance, and clinical decision support.

Transformative Shifts in the Genomics Landscape

The genomics landscape is undergoing a structural shift as sequencing migrates from centralized research laboratories into clinical pathways, decentralized testing models, and population-scale programs. Oncology remains a leading area of clinical adoption, supported by companion diagnostics, tumor profiling, liquid biopsy development, and therapy selection based on actionable genomic variants.

Rare disease diagnostics are also transforming care delivery. Whole-exome and whole-genome sequencing have shortened diagnostic odysseys for patients with suspected genetic disorders, while newborn sequencing pilots are evaluating how genomic screening can complement traditional metabolic screening. These applications are increasing demand for validated interpretation pipelines, genetic counseling capacity, and reimbursement models tied to clinical utility.

Another major shift is the convergence of genomics with multiomics. Organizations are integrating genomics with transcriptomics, proteomics, metabolomics, epigenomics, and real-world clinical data to improve disease stratification and biomarker discovery. This transition is expanding the value chain from sequencing instruments and consumables toward analytics platforms, cloud-native data architecture, and evidence-generation services.

Cumulative Impact of Artificial Intelligence on Genomics

Artificial intelligence is becoming a major force multiplier in genomics by improving variant calling, annotation, phenotype matching, protein structure prediction, drug target prioritization, and clinical trial design. Deep learning models have improved accuracy in sequence alignment, structural variant detection, and interpretation of complex genomic signals, while AI-enabled knowledge graphs help connect variants to disease mechanisms and therapeutic hypotheses.

The cumulative impact is especially visible in drug discovery and precision medicine. AI can reduce manual review burdens, identify patient subgroups, and support biomarker-driven development programs. The success of computational biology tools, including AI-based protein structure prediction, has strengthened confidence in data-driven life sciences research and accelerated investment in genomics-enabled discovery platforms.

However, the adoption of AI in genomics depends on data quality, transparency, bias mitigation, explainability, and regulatory alignment. Models trained on underrepresented populations can produce inequitable performance, making diverse reference datasets and rigorous validation essential. Organizations that combine AI capability with compliant data governance and clinically validated workflows are better positioned to scale genomic medicine responsibly.

Key Regional Insights for Genomics

Asia-Pacific is one of the fastest-developing genomics regions due to large population cohorts, expanding sequencing capacity, and strong government interest in precision medicine. China has invested heavily in sequencing infrastructure and population-scale research, while India's GenomeIndia initiative and growing biotechnology sector are strengthening local reference datasets. Japan, South Korea, Singapore, and Australia continue to advance clinical genomics through national research networks, cancer genomics programs, and hospital-linked sequencing initiatives.

North America remains a global leader because of its dense ecosystem of academic medical centers, biotechnology firms, diagnostic laboratories, cloud providers, and regulatory experience. The United States benefits from NIH-backed programs, FDA engagement on diagnostics and companion tests, and large-scale precision medicine adoption in oncology and rare disease. Canada contributes through provincial genomics networks, public health genomics, and population health research.

Europe is characterized by coordinated public investment, strong data protection standards, and cross-border genomics collaboration. The European Union's 1+ Million Genomes initiative and national programs in the United Kingdom, Germany, France, Italy, and Spain support clinical implementation and interoperable data frameworks. Latin America is gaining momentum through cancer genomics, infectious disease surveillance, and academic partnerships, with Brazil and Mexico playing important roles. The Middle East is advancing through national genome programs in Gulf countries, while Africa is becoming increasingly important for human genetic diversity research, pathogen genomics, and equitable reference dataset development.

Key Group Insights for Genomics

ASEAN is emerging as a strategically important genomics group because member states are investing in precision health, infectious disease surveillance, and biomedical research capacity. Singapore acts as a regional genomics hub with advanced infrastructure, while Thailand, Malaysia, Indonesia, Vietnam, and the Philippines are expanding laboratory networks and public health sequencing capabilities.

The GCC is accelerating genomics through national genome programs, population screening, and precision medicine investments, particularly in the United Arab Emirates, Saudi Arabia, and Qatar. These initiatives are supported by high digital health investment and a policy focus on inherited disease, preventive care, and localized reference genomes. The European Union is advancing a coordinated genomics model through common data standards, privacy frameworks, and cross-border research programs that aim to make genomic data more interoperable for healthcare and innovation.

BRICS countries represent a large share of the world's population and are increasingly relevant for diverse genomic datasets, domestic sequencing capacity, and cost-sensitive diagnostics. G7 countries continue to lead in regulatory science, clinical research, reimbursement policy, and advanced biopharmaceutical applications. NATO countries add relevance through biosecurity, pathogen surveillance, and resilience planning, where genomic epidemiology supports early detection and response to biological threats.

Key Country Insights for Genomics

The United States leads global genomics commercialization through strong venture investment, advanced diagnostic laboratories, NIH-funded research, and widespread oncology sequencing. Canada is advancing precision health through provincial programs and academic networks, while Mexico is building capacity in public health genomics, cancer diagnostics, and cross-border research. Brazil anchors Latin American genomics with academic sequencing networks, infectious disease surveillance experience, and growing precision oncology activity.

In Europe, the United Kingdom remains highly influential through Genomics England, NHS genomic medicine infrastructure, and the legacy of the 100,000 Genomes Project. Germany is strengthening clinical genomics through university hospitals and national genomics initiatives, France is advancing genomic medicine through its national healthcare strategy, and Italy and Spain are expanding cancer genomics, rare disease sequencing, and biobank-linked research. Russia maintains capabilities in biomedical research and population genetics, although international collaboration dynamics are shaped by geopolitical constraints.

In Asia-Pacific, China has developed large-scale sequencing capacity, domestic instrument and service provider ecosystems, and extensive population research. India is expanding its genomics base through GenomeIndia, a large patient population, and growth in affordable diagnostics. Japan emphasizes clinical quality, cancer research, and aging-related genomics, while Australia combines strong research universities with national genomics networks and rare disease initiatives. South Korea is advancing precision medicine through hospital-based sequencing, digital health infrastructure, and biotechnology investment.

Actionable Recommendations for Genomics Leaders

Industry leaders should prioritize clinically validated use cases where genomic testing demonstrably improves diagnosis, treatment selection, or patient management. Oncology, rare disease, reproductive health, pharmacogenomics, and infectious disease surveillance offer strong near-term opportunities when paired with clear evidence generation and payer engagement.

Organizations should invest in end-to-end workflow integration rather than isolated sequencing capacity. Scalable advantage comes from connecting sample logistics, automation, sequencing, bioinformatics, interpretation, reporting, genetic counseling, and longitudinal data capture. Partnerships with hospitals, reference laboratories, cloud infrastructure providers, and biopharmaceutical organizations can accelerate adoption while reducing implementation friction.

Data governance must be treated as a strategic capability. Leaders should build privacy-preserving architectures, ensure consent traceability, improve ancestry diversity in datasets, and validate AI models across populations. Organizations that align with regulatory expectations, reimbursement requirements, and clinical quality standards will be better positioned to earn trust and expand adoption of genomic medicine.

Research Methodology

This executive summary is based on a structured secondary research approach using verified public sources, regulatory references, peer-reviewed literature, national genomics program updates, public health agency materials, and industry-reported information. Sources considered include organizations such as the National Human Genome Research Institute, National Institutes of Health, World Health Organization, U.S. Food and Drug Administration, European Commission, Genomics England, and national precision medicine programs.

The analysis applies triangulation across technology trends, clinical adoption patterns, regional policy initiatives, funding signals, and ecosystem developments. Insights were evaluated for relevance to sequencing technologies, diagnostics, bioinformatics, AI-enabled genomics, population genomics, and clinical implementation.

The synthesis emphasizes data-backed interpretation without relying on unsupported claims. The methodology prioritizes verifiable evidence, cross-source validation, and practical implications for executive decision-making across healthcare, biotechnology, diagnostics, and life sciences.

Conclusion

Genomics is entering a new phase defined by clinical integration, AI-enabled interpretation, population-scale data generation, and multiomics convergence. The sector's strongest opportunities are linked to applications that prove clinical utility, reduce healthcare uncertainty, and support targeted treatment decisions.

Regional momentum is broadening beyond traditional innovation centers as Asia-Pacific, the Middle East, Latin America, and Africa invest in genomic infrastructure and localized reference datasets. At the same time, North America and Europe continue to shape regulatory models, clinical standards, and commercialization pathways.

Organizations that combine scientific rigor, scalable data systems, equitable datasets, responsible AI, and strong clinical partnerships will be best positioned to lead in the next generation of genomic medicine.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Genomics Market, by Product Type

• 7.1. Sequencing Platforms
  • 7.1.1. Next-Generation Sequencing (NGS) Platforms
  • 7.1.2. Sanger / Capillary Sequencing Platforms
• 7.2. Reagents & Consumables
  • 7.2.1. Enzymes & Master Mixes
  • 7.2.2. Library Preparation Kits
  • 7.2.3. Probes & Primers
• 7.3. Software & Analytics
  • 7.3.1. Gene Expression Analysis
  • 7.3.2. Variant Calling & Annotation Tools
• 7.4. Services
  • 7.4.1. Genomic Testing Services
  • 7.4.2. Genotyping & SNP Analysis
  • 7.4.3. Transcriptomics & Epigenomics Services

8. Genomics Market, by Technology

• 8.1. Array Technology
  • 8.1.1. Microarray Gene Expression
  • 8.1.2. SNP Genotyping Arrays
• 8.2. PCR Technology
• 8.3. DNA Sequencing
• 8.4. RNA Sequencing
  • 8.4.1. Bulk RNA Sequencing
  • 8.4.2. Single-Cell RNA Sequencing

9. Genomics Market, by Sample Type

• 9.1. Blood
• 9.2. Tissue
• 9.3. Saliva & Buccal Swabs
• 9.4. Cultured Cells

10. Genomics Market, by Automation Level

• 10.1. Manual
• 10.2. Semi-Automated
• 10.3. Fully Automated

11. Genomics Market, by Application

• 11.1. Agriculture
  • 11.1.1. Animal Genomics
  • 11.1.2. Crop Genomics
• 11.2. Diagnostics
  • 11.2.1. Cancer Genomics
  • 11.2.2. Genetic Testing
  • 11.2.3. Infectious Disease Testing
• 11.3. Drug Discovery & Development
  • 11.3.1. Biomarker Discovery
  • 11.3.2. Target Identification
• 11.4. Personalized Medicine
  • 11.4.1. Companion Diagnostics
  • 11.4.2. Precision Therapeutics

12. Genomics Market, by End User

• 12.1. Academic & Government Institutes
• 12.2. Commercial Research Organizations
• 12.3. Hospitals & Clinics
• 12.4. Pharmaceutical & Biotechnology Companies

13. Genomics Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Genomics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Genomics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. 10x Genomics, Inc.
• 17.2. 23andMe Holding Co.
• 17.3. Agilent Technologies, Inc.
• 17.4. BGI Genomics Co., Ltd.
• 17.5. Bio-Rad Laboratories, Inc.
• 17.6. Centogene N.V.
• 17.7. Danaher Corporation
• 17.8. EPIC Sciences, Inc.
• 17.9. Eurofins Scientific SE
• 17.10. F. Hoffmann-La Roche Ltd.
• 17.11. Gencove, Inc.
• 17.12. GenScript Biotech Corporation
• 17.13. Guardant Health, Inc.
• 17.14. Helix OpCo, LLC
• 17.15. Illumina, Inc.
• 17.16. Invitae Corporation
• 17.17. Merck & Co., Inc.
• 17.18. Myriad Genetics Laboratories, Inc.
• 17.19. Natera, Inc.
• 17.20. Oxford Nanopore Technologies PLC
• 17.21. Pacific Biosciences of California, Inc.
• 17.22. Personalis, Inc.
• 17.23. Quest Diagnostics
• 17.24. SomaLogic, Inc.
• 17.25. Sophia Genetics SA
• 17.26. Thermo Fisher Scientific Inc.
• 17.27. Twist Bioscience Corporation